Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:
based on the National Health Claims Database 2017-2019
Osteoporos Int 2024 Jan 19. doi: 10.1007/s00198-024-07022-7 Can be viewed at DeepDyve 1 month free trial
Seong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3
4X reduction in hip fractures in those who happened to be prescribed
to take some amount of Vitamin D in addition to SERMS
With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.
Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.
Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.
Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio HR, 0.77; 95% confidence interval CI, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group.
Analysis for specific fractures showed a lower hazard of hip fracture in the SERM + VitD group (HR, 0.25; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.
Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.
26 References
- Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed
- Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8 - DOI - PubMed - PMC
- Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed
- Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007 - DOI - PubMed - PMC
- Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCO - DOI - PubMed - PMC
- Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-x - DOI - PubMed
- Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7 - DOI - PubMed - PMC
- Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed
- Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969
- Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52
- Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721 - DOI - PubMed
- Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed
- Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed
- Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645
- Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112 - DOI - PubMed - PMC
- Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed
- Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed
- LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106 - DOI - PubMed - PMC
- Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016 - DOI - PubMed
- Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032 - DOI - PubMed
- Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115
- Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed
- Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193 - DOI - PubMed - PMC
- Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC
- Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC
- Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4 - DOI - PubMed
76+ Hip fracture studies in VitaminDWiki
This list is automatically updated
VitaminDWiki – Falls and Fractures category
258 items in FALLS and FRACTURES - Vitamin D and Calcium cost-effectively reduce falls and fractures – April 2019
- see also Overview Seniors and Vitamin D
Falls
- Fall prevention - Vitamin D is one of the ways - umbrella review Jan 2024
- Deaths due to falls doubled in just a decade (age-adjusted, perhaps decreased vitamin D) – June 2019
- Preventing Falls in Older Adults – Vitamin D combination is the best - JAMA Meta-analysis Nov 2017
- Falls cut in half by 100,000 IU vitamin D monthly - RCT 2016
- Falls reduced by a third if achieved 40 ng level vitamin D– RCT Sept 2018
- Note: It took 6 months to get to that level. Most trials last only 3 months
- Vitamin D prevents falls – majority of meta-analyses conclude – meta-meta analysis Feb 2015
- Falls reduced by Vitamin D: 13 percent reduction if more than 700 IU – review of 38 trials – Aug 2022
Left hand column section as of Nov 2024
Ankle (16+)Bone Mineral Density (28+)Children (16+)Hip Fractures (68+)Vertigo (22+)Fracture
- Hip fractures are predicted by 10 factors – low Vitamin D is the biggest – Aug 2023
- Vitamin D and fractures – 24 meta-analyses and counting – Dec 2014
- Low trauma bone fractures in seniors – considering Vitamin D loading dose for all, without testing – Nov 2019
- Vitamin K (any amount and any kind) reduced bone fractures by 24 percent – meta-analysis – May 2019
- 77+ Hip fracture items in VitaminDWiki title Click here for details examples:
Hip fracture risk was reduced by 4 times when Vitamin D was added to SERMS - Jan 20242311 visitors, last modified 25 Jan, 2024, This page is in the following categories (# of items in each category)